- Zacks
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.
- Motley Fool
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
The latest bull market has plenty of intriguing buying opportunities.
- Motley Fool
2 Superior Growth Stocks to Buy if You Have $1,000 Right Now
Growth stocks with wide moats and strong financials can compound investor returns with time.
